Drug intelligence / Profile preview

GS300

Development stage: Unknown
Lead developer: Gelesis
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Oral

Overview

GS300 is an orally administered, non-absorbed, proprietary hydrogel developed by Gelesis for the treatment of nonalcoholic fatty liver disease (NAFLD), obesity, and potentially related metabolic disorders. Taken before meals, GS300 capsules mix with ingested food and increase the elasticity and volume of the stomach and small intestine contents, promoting satiety and reducing food intake. Preclinical data suggest GS300 may reduce weight, decrease hepatic fat, improve intestinal barrier function, and mitigate high fat diet-induced intestinal alterations and hepatic steatosis. GS300 is currently being investigated in clinical trials for NAFLD and related metabolic conditions.

Other names: GS300GS-300GS 300Gel-B

Beyond the preview

Go deeper on GS300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS300.

Explore the full profile